SCHEMBL879253

SCHEMBL879253

CNC(=O)c1ccc(N)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
POLB P06746 1/20 0.53
PLAU P00749 1/20 0.49
HDAC6 Q9UBN7 3/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC2 Q92769 1/20 0.47
KDM4E B2RXH2 2/20 0.46
HPGD P15428 3/20 0.46
CA2 P00918 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 2/20 0.44
HTT P42858 1/20 0.44
HDAC1 Q13547 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30071572 1.00 ALDH1A1 (0.53) ALDH1A1POLBPLAUHDAC6HDAC8
SCHEMBL613262 0.85 KDM4E (0.62) PLAUHDAC6HDAC8HDAC2KDM4E
SCHEMBL4161973 0.82 MEN1 (0.61) ALDH1A1POLBHDAC6HDAC8HDAC2
SCHEMBL29582662 0.82 PLAU (0.53) ALDH1A1PLAUHDAC6HDAC8HDAC2
SCHEMBL940919 0.82 PLAU (0.53) ALDH1A1PLAUHDAC6HDAC8HDAC2
SCHEMBL12200767 0.81 ALDH1A1 (0.49) ALDH1A1POLBHDAC6KDM4EHPGD
SCHEMBL3111273 0.81 KDM4E (0.54) ALDH1A1POLBHDAC6HDAC8KDM4E
SCHEMBL16147608 0.81 POLB (0.45) ALDH1A1POLBHDAC6KDM4ESMN1; SMN2
SCHEMBL2662442 0.79 HSP90AA1 (0.53) ALDH1A1PLAUHDAC6HDAC8HDAC2
SCHEMBL8918916 0.79 NPC1 (0.54) ALDH1A1POLBHDAC6HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101870824-B Method for preparing azo colouring agent by utilizing supergravity reactor UNIV BEIJING CHEMICAL 2013-05-01 CN claimed
CN-101870824-A Method for preparing azo colouring agent by utilizing supergravity reactor UNIV BEIJING CHEMICAL 2010-10-27 CN claimed
US-6548647-B2 Spraying coupling components in solution or suspension to collide in reactor chamber, then pressurizing to remove; useful for offset printing inks CLARIANT GMBH (DE) 2003-04-15 US claimed
US-20020055619-A1 Process for preparing azo colorants CLARIANT GMBH 2002-05-09 US claimed
EP-1195411-A1 Process for the preparation of azo colourants Clariant GmbH (DE) 2002-04-10 EP claimed
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
US-11957683-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
US-11952374-B2 Bicyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 US disclosed
CN-116724038-A Bicyclic compounds 安力高医药股份有限公司 2023-09-08 CN disclosed
EP-4232450-A1 BICYCLIC COMPOUNDS Aligos Therapeutics, Inc. (US) 2023-08-30 EP disclosed
CN-111601807-B Exo-azaspiro inhibitors of MENIN-MLL interactions 詹森药业有限公司 2023-03-31 CN disclosed
CN-1398282-A Method for producing azo colorants in microreactors CLARIANT INT LTD (CH) 2003-02-19 CN disclosed
EP-1257602-A1 METHOD FOR PRODUCTION OF AZO DYES IN MICROREACTORS CLARIANT INTERNATIONAL LTD. (CH) 2002-11-20 EP disclosed
US-6469147-B2 DIAZOTIZATION CLARIANT FINANCE (BVI) LIMITED (VG) 2002-10-22 US disclosed
US-20020055619-A1 Process for preparing azo colorants CLARIANT GMBH 2002-05-09 US disclosed
EP-1195411-A1 Process for the preparation of azo colourants Clariant GmbH (DE) 2002-04-10 EP disclosed
US-20010029294-A1 Preparation of azo colorants in microreactors CLARIANT INTERNATIONAL LTD. 2001-10-11 US disclosed
WO-2001059013-A1 METHOD FOR PRODUCTION OF AZO DYES IN MICROREACTORS CLARIANT INTERNATIONAL LTD (CH) 2001-08-16 WO disclosed
US-4031073-A Monoazo pigments containing barbituric acid or thio- or imino-derivatives thereof CIBA-GEIGY CORPORATION (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952374-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 ALDH1A1 543/4885POLB 3123/4885PLAU 2569/4885
US-11957683-B2 Bicyclic compounds SLC10A1, PKD1, CYP11B2 ALDH1A1 543/4885POLB 3123/4885PLAU 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.